FDA Oks Valeant toenail fungus treatment Jublia
from The Associated Press via BloombergBusinessweek
The Food and Drug Administration has approved a toenail fungus treatment from Valeant Pharmaceuticals International Inc. that could reach $800 million in peak U.S. sales, according to the Canadian drugmaker. Valeant plans to launch the topical treatment, Jublia, in the third quarter in the United States.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063